TNF-α-induced down-regulation of CDX2 suppresses MEP1A expression in colitis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 6, 2012, Pages 843-851

  Coskun, Mehmet ^a,b   Olsen, Anders Krüger ^b,c   Holm, Thomas Lindebo ^d   Kvist, Peter Helding ^d   Nielsen, Ole Haagen ^a   Riis, Lene Buhl ^a   Olsen, Jørgen ^b   Troelsen, Jesper Thorvald ^e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Hospital South   (Denmark)

^d NOVO NORDISK A S   (Denmark)

^e ROSKILDE UNIVERSITY   (Denmark)

Author keywords

DSS colitis; Inflammatory bowel disease; Infliximab; Intestine; Tumor necrosis factor; Ulcerative colitis

Indexed keywords

DEXTRAN SULFATE; INFLIXIMAB; MESSENGER RNA; TRANSCRIPTION FACTOR CDX2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; COLITIS; COLON BIOPSY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MEPRIN 1A GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; COLITIS, ULCERATIVE; DEXTRAN SULFATE; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; METALLOENDOPEPTIDASES; MICE; MIDDLE AGED; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858984691     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.01.012     Document Type: Article

References (51)

1. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
2. Garrett W.S., Gordon J.I., Glimcher L.H. Homeostasis and inflammation in the intestine. Cell 2010, 140:859-870.
3. Suh E., Chen L., Taylor J., Traber P.G. A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol. Cell. Biol. 1994, 14:7340-7351.
4. Funakoshi S., Kong J., Crissey M.A., Dang L., Dang D., Lynch J.P. Intestine-specific transcription factor Cdx2 induces E-cadherin function by enhancing the trafficking of E-cadherin to the cell membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G1054-G1067.
5. Alkhoury F., Malo M.S., Mozumder M., Mostafa G., Hodin R.A. Differential regulation of intestinal alkaline phosphatase gene expression by Cdx1 and Cdx2. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G285-G290.
6. Troelsen J.T., Mitchelmore C., Spodsberg N., Jensen A.M., Noren O., Sjostrom H. Regulation of lactase-phlorizin hydrolase gene expression by the caudal-related homoeodomain protein Cdx-2. Biochem. J. 1997, 322:833-838.
7. Colnot S., Romagnolo B., Lambert M., Cluzeaud F., Porteu A., Vandewalle A., Thomasset M., Kahn A., Perret C. Intestinal expression of the calbindin-D9K gene in transgenic mice. Requirement for a Cdx2-binding site in a distal activator region. J. Biol. Chem. 1998, 273:31939-31946.
8. Hinoi T., Gesina G., Akyol A., Kuick R., Hanash S., Giordano T.J., Gruber S.B., Fearon E.R. CDX2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. Gastroenterology 2005, 128:946-961.
9. Gao N., White P., Kaestner K.H. Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. Dev. Cell 2009, 16:588-599.
10. Suh E., Traber P.G. An intestine-specific homeobox gene regulates proliferation and differentiation. Mol. Cell. Biol. 1996, 16:619-625.
11. Barrett J.C., Lee J.C., Lees C.W., Prescott N.J., Anderson C.A., Phillips A., Wesley E., Parnell K., Zhang H., Drummond H., Nimmo E.R., Massey D., Blaszczyk K., Elliott T., Cotterill L., Dallal H., Lobo A.J., Mowat C., Sanderson J.D., Jewell D.P., Newman W.G., Edwards C., Ahmad T., Mansfield J.C., Satsangi J., Parkes M., Mathew C.G., Donnelly P., Peltonen L., Blackwell J.M., Bramon E., Brown M.A., Casas J.P., Corvin A., Craddock N., Deloukas P., Duncanson A., Jankowski J., Markus H.S., Mathew C.G., McCarthy M.I., Palmer C.N., Plomin R., Rautanen A., Sawcer S.J., Samani N., Trembath R.C., Viswanathan A.C., Wood N., Spencer C.C., Barrett J.C., Bellenguez C., Davison D., Freeman C., Strange A., Donnelly P., Langford C., Hunt S.E., Edkins S., Gwilliam R., Blackburn H., Bumpstead S.J., Dronov S., Gillman M., Gray E., Hammond N., Jayakumar A., McCann O.T., Liddle J., Perez M.L., Potter S.C., Ravindrarajah R., Ricketts M., Waller M., Weston P., Widaa S., Whittaker P., Deloukas P., Peltonen L., Mathew C.G., Blackwell J.M., Brown M.A., Corvin A., McCarthy M.I., Spencer C.C., Attwood A.P., Stephens J., Sambrook J., Ouwehand W.H., McArdle W.L., Ring S.M., Strachan D.P. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat. Genet. 2009, 41:1330-1334.
12. Banerjee S., Oneda B., Yap L.M., Jewell D.P., Matters G.L., Fitzpatrick L.R., Seibold F., Sterchi E.E., Ahmad T., Lottaz D., Bond J.S. MEP1A allele for meprin A metalloprotease is a susceptibility gene for inflammatory bowel disease. Mucosal. Immunol. 2009, 2:220-231.
13. Zucchelli M., Torkvist L., Bresso F., Halfvarson J., Hellquist A., Anedda F., Assadi G., Lindgren G.B., Svanfeldt M., Janson M., Noble C.L., Pettersson S., Lappalainen M., Paavola-Sakki P., Halme L., Farkkila M., Turunen U., Satsangi J., Kontula K., Lofberg R., Kere J., D'Amato M. PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. Inflamm. Bowel Dis. 2009, 15:1562-1569.
14. Zeissig S., Burgel N., Gunzel D., Richter J., Mankertz J., Wahnschaffe U., Kroesen A.J., Zeitz M., Fromm M., Schulzke J.D. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007, 56:61-72.
15. Moehle C., Ackermann N., Langmann T., Aslanidis C., Kel A., Kel-Margoulis O., Schmitz-Madry A., Zahn A., Stremmel W., Schmitz G. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J. Mol. Med. 2006, 84:1055-1066.
16. Darsigny M., Babeu J.P., Dupuis A.A., Furth E.E., Seidman E.G., Levy E., Verdu E.F., Gendron F.P., Boudreau F. Loss of hepatocyte-nuclear-factor-4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice. PLoS One 2009, 4:e7609.
17. Banerjee S., Jin G., Bradley S.G., Matters G.L., Gailey R.D., Crisman J.M., Bond J.S. Balance of meprin A and B in mice affects the progression of experimental inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 300:G273-G282.
18. Van der Sluis M., De Koning B.A., De Bruijn A.C., Velcich A., Meijerink J.P., Van Goudoever J.B., Buller H.A., Dekker J., Van Seuningen I., Renes I.B., Einerhand A.W. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006, 131:117-129.
19. Boyd M., Hansen M., Jensen T.G., Perearnau A., Olsen A.K., Bram L.L., Bak M., Tommerup N., Olsen J., Troelsen J.T. Genome-wide analysis of CDX2 binding in intestinal epithelial cells (Caco-2). J. Biol. Chem. 2010, 285:25115-25125.
20. Shimakura J., Terada T., Shimada Y., Katsura T., Inui K. The transcription factor Cdx2 regulates the intestine-specific expression of human peptide transporter 1 through functional interaction with Sp1. Biochem. Pharmacol. 2006, 71:1581-1588.
21. Yamamoto H., Bai Y.Q., Yuasa Y. Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem. Biophys. Res. Commun. 2003, 300:813-818.
22. Sakaguchi T., Gu X., Golden H.M., Suh E., Rhoads D.B., Reinecker H.C. Cloning of the human claudin-2 5'-flanking region revealed a TATA-less promoter with conserved binding sites in mouse and human for caudal-related homeodomain proteins and hepatocyte nuclear factor-1alpha. J. Biol. Chem. 2002, 277:21361-21370.
23. Zheng X., Tsuchiya K., Okamoto R., Iwasaki M., Kano Y., Sakamoto N., Nakamura T., Watanabe M. Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm. Bowel Dis. 2011, 17:2251-2260.
24. Sipos F., Muzes G., Valcz G., Galamb O., Toth K., Leiszter K., Krenacs T., Tulassay Z., Molnar B. Regeneration associated growth factor receptor and epithelial marker expression in lymphoid aggregates of ulcerative colitis. Scand. J. Gastroenterol. 2010, 45:440-448.
25. Bertenshaw G.P., Turk B.E., Hubbard S.J., Matters G.L., Bylander J.E., Crisman J.M., Cantley L.C., Bond J.S. Marked differences between metalloproteases meprin A and B in substrate and peptide bond specificity. J. Biol. Chem. 2001, 276:13248-13255.
26. Kruse M.N., Becker C., Lottaz D., Kohler D., Yiallouros I., Krell H.W., Sterchi E.E., Stocker W. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem. J. 2004, 378:383-389.
27. Calon A., Gross I., Lhermitte B., Martin E., Beck F., Duclos B., Kedinger M., Duluc I., Domon-Dell C., Freund J.N. Different effects of the Cdx1 and Cdx2 homeobox genes in a murine model of intestinal inflammation. Gut 2007, 56:1688-1695.
28. Kim S., Domon-Dell C., Wang Q., Chung D.H., Di C.A., Pandolfi P.P., Freund J.N., Evers B.M. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology 2002, 123:1163-1178.
29. MacDonald T.T., Hutchings P., Choy M.Y., Murch S., Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immunol. 1990, 81:301-305.
30. Breese E.J., Michie C.A., Nicholls S.W., Murch S.H., Williams C.B., Domizio P., Walker-Smith J.A., MacDonald T.T. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994, 106:1455-1466.
31. Nielsen O.H., Seidelin J.B., Munck L.K., Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J. Intern. Med. 2011, 270:15-28.
32. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987, 317:1625-1629.
33. Coskun M., Boyd M., Olsen J., Troelsen J.T. Control of intestinal promoter activity of the cellular migratory regulator gene ELMO3 by CDX2 and SP1. J. Cell. Biochem. 2010, 109:1118-1128.
34. Seidelin J.B., Bjerrum J.T., Coskun M., Widjaya B., Vainer B., Nielsen O.H. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol. Lett. 2010, 128:80-85.
35. Seidelin J.B., Horn T., Nielsen O.H. Simple and efficient method for isolation and cultivation of endoscopically obtained human colonocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285:G1122-G1128.
36. Guo R.J., Funakoshi S., Lee H.H., Kong J., Lynch J.P. The intestine-specific transcription factor Cdx2 inhibits {beta}-catenin/TCF transcriptional activity by disrupting the {beta}-catenin/ TCF protein complex. Carcinogenesis 2009, 31:159-166.
37. Murthy S.N., Cooper H.S., Shim H., Shah R.S., Ibrahim S.A., Sedergran D.J. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig. Dis. Sci. 1993, 38:1722-1734.
38. Frank S.R., Schroeder M., Fernandez P., Taubert S., Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 2001, 15:2069-2082.
39. Coskun M., Troelsen J.T., Nielsen O.H. The role of CDX2 in intestinal homeostasis and inflammation. Biochim. Biophys. Acta 2011, 1812:283-289.
40. Cooper H.S., Murthy S.N., Shah R.S., Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 1993, 69:238-249.
41. Abraham C., Cho J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009, 361:2066-2078.
42. Vallee S., Laforest S., Fouchier F., Montero M.P., Penel C., Champion S. Cytokine-induced upregulation of NF-kappaB, IL-8, and ICAM-1 is dependent on colonic cell polarity: implication for PKCdelta. Exp. Cell Res. 2004, 297:165-185.
43. Bradley J.R. TNF-mediated inflammatory disease. J. Pathol. 2008, 214:149-160.
44. Coskun M., Olsen J., Seidelin J.B., Nielsen O.H. MAP kinases in inflammatory bowel disease. Clin. Chim. Acta 2011, 412:513-520.
45. Ryu J.H., Kim S.H., Lee H.Y., Bai J.Y., Nam Y.D., Bae J.W., Lee D.G., Shin S.C., Ha E.M., Lee W.J. Innate immune homeostasis by the homeobox gene caudal and commensal-gut mutualism in Drosophila. Science 2008, 319:777-782.
46. Stegmann A., Hansen M., Wang Y., Larsen J.B., Lund L.R., Ritie L., Nicholson J.K., Quistorff B., Simon-Assmann P., Troelsen J.T., Olsen J. Metabolome, transcriptome, and bioinformatic cis-element analyses point to HNF-4 as a central regulator of gene expression during enterocyte differentiation. Physiol. Genomics 2006, 27:141-155.
47. Ahn S.H., Shah Y.M., Inoue J., Morimura K., Kim I., Yim S., Lambert G., Kurotani R., Nagashima K., Gonzalez F.J., Inoue Y. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm. Bowel Dis. 2008, 14:908-920.
48. Boyd M., Bressendorff S., Moller J., Olsen J., Troelsen J.T. Mapping of HNF4alpha target genes in intestinal epithelial cells. BMC Gastroenterol. 2009, 9:68.
49. Nikolaidou-Neokosmidou V., Zannis V.I., Kardassis D. Inhibition of hepatocyte nuclear factor 4 transcriptional activity by the nuclear factor kappaB pathway. Biochem. J. 2006, 398:439-450.
50. Arijs I., De H.G., Lemaire K., Quintens R., Van L.L., Van S.K., Leemans P., Cleynen I., Van A.G., Vermeire S., Geboes K., Schuit F., Rutgeerts P. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 2009, 4:e7984.
51. Arijs I., De H.G., Machiels K., Van S.K., Lemaire K., Schraenen A., Van L.L., Quintens R., Van A.G., Vermeire S., Schuit F., Rutgeerts P. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am. J. Gastroenterol. 2011, 106:748-761.